Cancer

Our combination of comprehensive tumor markers and harmonized instrument families provide your laboratory with clinically relevant results for the most debilitating, costly and commonly occurring cancers. Rediscover personalized oncology testing solutions for early detection, diagnosis and monitoring needs.

For in vitro diagnostic use only.

Early Detection

The clinical laboratory can play a key role in the early detection of cancer, which may greatly increase the chances of successful treatment.

Effective Management

Oncology biomarkers can provide affordable, reliable, accurate, non-invasive, and sensitive information to help effectively manage cancer.

Oncology Biomarkers

Approximately 1 in 5 women will develop a pelvic mass in their lifetime. The Risk of Ovarian Malignancy Algorithm (ROMA) calculation can help determine the likelihood that this mass is a malignancy prior to surgery.

The global burden of ovarian cancer

Epithelial ovarian cancer is the fifth leading cause of cancer deaths in women worldwide.1 Due to current testing limitations and its non-specific symptoms, ovarian cancer is diagnosed at an advanced stage in more than 70% of patients.2 The associated poor prognosis and intensive treatment pathway places a heavy burden on patients, their caregivers, and their loved ones.

BUT IT DOESN’T ALWAYS HAVE TO BE LIKE THIS.

For many women facing ovarian cancer, we can help clinicians make more informed decisions for their patients on risk stratification, monitoring and recurrence of progressive disease.

Because it's more than a test. It's her life.

 
 
     

 


 

laboratory-personnel_450x240.jpg
ASSAYS ENGINEERED TO PROVIDE RELIABLE ASSISTANCE IN CANCER DIAGNOSIS AND MONITORING OF PATIENT RESPONSE TO THERAPY 

Abbott offers a wide variety of assays to test for many types of cancers including, breast, colon, gastrointestinal, liver, ovarian, pancreatic, testicular and prostate cancer. The Abbott oncology solution can help you reduce laboratory operational costs while maintaining the quality standards necessary to have a meaningful positive impact to the quality and cost of health care.

CORE LABORATORY Menu
References
  1. Brodsky BS, Owens GM, Scotti DJ, et al. Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers. Am Health Drug Benefits. 2017;10(7):351-9.
  2. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109(3):370-6.

    You are about to exit the Abbott family of websites for a 3rd party website

    Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

    Do you wish to continue and exit this website?

    Yes No

    You are about to enter an Abbott country or region specific website.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

    Do you wish to continue and enter this website?

    Yes No

    DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

    Content is not under the control of corelaboratory.abbott.

    Yes No